DB01393ApprovedInvestigationalSmall moleculeFibric Acid DerivativesHypolipidemic Agents Indicated for Hyperlipidemia
Bezafibrate is a lipid-lowering fibrate used in the management of primary and secondary hyperlipidaemia, when there is a lack of clinical improvement following lifestyle modifications or correction of the underlying disorder. Antilipemic agent that lowers cholesterol and triglycerides.
- Mechanism
- Curator reviewed
It is generally accepted that bezafibrate is likely an agonist of PPAR-alpha. However, certain other investigations have also suggested that the substance might also elicit some effects on PPAR-gamma and PPAR-delta too.
- Primary indication
- For the treatment of primary hyperlipidaemia types IIa, IIb, III, IV and V (Fredrickson classification) corresponding to groups I, II and III of the European Atherosclerosis Society guidelines - when diet alone or improvements in...Curator reviewed · 4 structured indications
- Formula / weight
- C19H20ClNO4 · 361.819 g/mol (avg)
- First approval
- Canada, 1998
- Code names
- BM 15.075
- Brand names
Resolves to
Clinical / RWD
Structure
InChIKey
IIBYAHWJQTYFKB-UHFFFAOYSA-NSMILESCC(C)(OC1=CC=C(CCNC(=O)C2=CC=C(Cl)C=C2)C=C1)C(O)=OTransporters
What you can answer from here — as of September 23, 2026
8Protein targetsEach mapped to UniProt, with action and pharmacological actionListed above
1TransporterSubstrate / inhibitor direction, not just membershipListed above
Which drugs share a target with Bezafibrate, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account